lenvatinib

0:01:47

Dr. Finn Discusses the Role of Lenvatinib in Liver Cancer

0:01:28

Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer

0:01:22

Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

0:01:39

Dr. Bastholt on Lenvatinib in Thyroid Cancer

0:01:32

Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer

0:01:40

Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCC

0:05:19

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

0:00:59

Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC

0:00:57

Dr. Taylor Discusses the Toxicities and Impact of Lenvatinib in the SELECT Trial

0:07:37

Lenvatinib As Up-front Therapy for Unresectable HCC

0:01:23

Dr. Brose Discusses Lenvatinib for the Treatment of Patients With Thyroid Cancer

0:01:42

When to Consider Lenvatinib

0:00:49

CLEAR: lenvatinib and pembrolizumab in advanced renal cell carcinoma

0:02:57

ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005

0:06:42

The Role of Lenvatinib in Advanced RCC

0:03:32

24mg versus 18mg starting dose of lenvatinib for differentiated thyroid cancer

0:02:06

Lenvatinib plus pembro for aRCC - update on the CLEAR study

0:03:56

Lenvatinib: Exploring Dose Reductions and Interruptions

0:01:31

Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer

0:00:55

PEMMELA cohort 2: second line pembrolizumab and lenvatinib in PM

0:00:59

Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale

0:01:39

Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer

0:01:00

Lenvatinib in Thyroid Cancer With and Without VEGF-Targeted Therapy

0:01:44

Assessing lenvatinib with pembrolizumab in advanced renal cell carcinoma